{"schema_version":"secwatch.filing_event.v1","accession":"0001789769-24-000082","form_type":"8-K","ticker":"TIL","cik":"0001789769","company_name":"Instil Bio, Inc.","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.533519+00:00","generated_at":"2026-05-31T09:46:13.412426+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Instil Bio Q2 net loss $2.29/share; in-licenses two assets, leases facility to AstraZeneca","bullets":["Net loss per share $2.29 (GAAP), non-GAAP $1.57 for Q2 2024; improved from $2.87 and $2.03 in Q2 2023.","Cash, equivalents, marketable securities and long-term investments $152.6M as of June 30, expected runway beyond 2026.","In-licensed SYN-2510 (PD-L1xVEGF bispecific) and SYN-27M (ADCC-enhanced anti-CTLA-4) from ImmuneOnco for exclusive global rights outside Greater China.","Executed 15-year lease of cell therapy manufacturing facility to AstraZeneca; initial base rent >$7.5M annually escalating at 3%.","R&D expenses fell to $2.9M in Q2 2024 from $8.5M in Q2 2023; restructuring and impairment charges minimal."],"urls":{"canonical":"https://secwatch.observer/filing/0001789769-24-000082","json":"https://secwatch.observer/filing/0001789769-24-000082.json","markdown":"https://secwatch.observer/filing/0001789769-24-000082.md","text":"https://secwatch.observer/filing/0001789769-24-000082.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789769/000178976924000082/0001789769-24-000082-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789769/000178976924000082/til-20240813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:46:13.412426+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}